B.Riley Starts 4D Molecular Therapeutics (FDMT) at Buy

July 31, 2026 3:20 AM

B.Riley analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found